YONGIN, South Korea, April 2, 2024 /PRNewswire/ -- GC Cell, a fully integrated cell therapy pioneer has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphoma, and real-world data for the anticancer immunotherapy drug 'Immuncell-LC' at the AACR Annual Meeting 2024 that will take place in San Diego, California, on April 5-10.
YONGIN, South Korea, April 3, 2023 /PRNewswire/ -- GC Cell, a Korean biotech company, announced on Mar. 28th that it had held the 12th General Shareholders' Meeting at GC Biopharma R&D Center in Yongin, Gyeonggi-do of South Korea and resolved some major agenda items, including the appointment of inside directors.
YONGIN, SOUTH KOREA & NEWARK, N.J.--(BUSINESS WIRE)--GC corp. (KOSPI: 005250), the holding (system) company for GC group in South Korea with major operating companies in across healthcare sectors, today announced that it has signed a definitive agreement to acquire 100% of the shares of BioCentriq, Inc., a pioneering US-based contract development and manufacturing organization (CDMO) that designs and develops scalable cell and gene technologies. This cross-border acquisition broadens GC companies’ capabilities in scaling CDMO platforms.
YONGIN, South Korea & MUMBAI, India--(BUSINESS WIRE)--GC Cell (KOSDAQ:144510) and Rivaara Immune Private Limited today announced that they have entered into an exclusive licensing agreement, pursuant to which Rivaara Immune has agreed to develop and commercialize Immuncell-LC® in India, Sri Lanka, and Bangladeshi. Developed by GC Cell, Immuncell-LC® is a patient-derived autologous T-cell immunotherapy for liver cancer, which was approved by the Korean MFDS back in 2007.